172 related articles for article (PubMed ID: 25457868)
1. Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy?
Nakonechna A; Hills J; Moor J; Dore P; Abuzakouk M
Ann Allergy Asthma Immunol; 2015 Jan; 114(1):73-4. PubMed ID: 25457868
[No Abstract] [Full Text] [Related]
2. Clinical trial shows sublingual immunotherapy to be effective for treatment of children with grass pollen allergy.
Wilkinson J
Immunotherapy; 2012 Nov; 4(11):1091-2. PubMed ID: 23194357
[No Abstract] [Full Text] [Related]
3. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
4. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
5. An extract of Timothy-grass pollen used as sublingual immunotherapy for summer hay fever.
Kay AB
Drugs Today (Barc); 2007 Dec; 43(12):841-8. PubMed ID: 18174969
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy.
Frew AJ
N Engl J Med; 2008 May; 358(21):2259-64. PubMed ID: 18499568
[No Abstract] [Full Text] [Related]
7. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.
Stelmach I; Kaluzińska-Parzyszek I; Jerzynska J; Stelmach P; Stelmach W; Majak P
Allergy; 2012 Mar; 67(3):312-20. PubMed ID: 22142341
[TBL] [Abstract][Full Text] [Related]
8. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
9. SQ-standardised grass tablet sublingual immunotherapy: persistent clinical benefit and progressive immunological changes during three years treatment.
Durham SR
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():121-7; discussion 127-31. PubMed ID: 20799452
[No Abstract] [Full Text] [Related]
10. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
11. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
12. A short assessment of sublingual immunotherapy.
Rakoski J; Wessner D
Int Arch Allergy Immunol; 2001 Nov; 126(3):185-7. PubMed ID: 11752874
[No Abstract] [Full Text] [Related]
13. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data.
Ariano R; Panzani RC; Mistrello G
Eur Ann Allergy Clin Immunol; 2005 Mar; 37(3):103-8. PubMed ID: 15918297
[TBL] [Abstract][Full Text] [Related]
15. Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation.
Hsiao KC; Smart J
Pediatr Allergy Immunol; 2014 Nov; 25(7):714-5. PubMed ID: 25200920
[No Abstract] [Full Text] [Related]
16. Anaphylaxis caused by allergen sublingual immunotherapy?
André C; Fadel R
Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
[No Abstract] [Full Text] [Related]
17. Which allergen extract for grass pollen immunotherapy? An in vitro study.
Marcucci F; Sensi L; Di Cara G; Incorvaia C; Puccinelli P; Scurati S; Frati F
Immunol Invest; 2010; 39(6):635-44. PubMed ID: 20653430
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
[TBL] [Abstract][Full Text] [Related]
19. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.
Howarth P; Malling HJ; Molimard M; Devillier P
Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377
[TBL] [Abstract][Full Text] [Related]
20. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
Panzner P; Petráš M; Sýkora T; Lesná IK; Liška M
Allergy Asthma Proc; 2011; 32(2):142-50. PubMed ID: 21439167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
